ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 112 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $81,268 | -73.9% | 11,864 | -60.6% | 0.00% | – |
| Q2 2023 | $311,899 | -49.6% | 30,077 | -60.7% | 0.00% | – |
| Q1 2023 | $619,225 | +115.0% | 76,542 | +318.6% | 0.00% | – |
| Q4 2022 | $288,005 | +121.5% | 18,286 | +120.8% | 0.00% | – |
| Q3 2022 | $130,000 | -30.5% | 8,283 | -38.4% | 0.00% | – |
| Q2 2022 | $187,000 | +29.0% | 13,439 | +60.1% | 0.00% | – |
| Q1 2022 | $145,000 | -43.4% | 8,392 | -52.3% | 0.00% | – |
| Q4 2021 | $256,000 | -41.6% | 17,591 | -27.7% | 0.00% | – |
| Q3 2021 | $438,000 | +177.2% | 24,343 | +170.1% | 0.00% | – |
| Q2 2021 | $158,000 | +1.3% | 9,013 | +46.0% | 0.00% | – |
| Q1 2021 | $156,000 | -43.3% | 6,173 | -85.5% | 0.00% | – |
| Q4 2020 | $275,000 | +2650.0% | 42,475 | +331.7% | 0.00% | – |
| Q1 2020 | $10,000 | -16.7% | 9,838 | +59.0% | 0.00% | – |
| Q4 2019 | $12,000 | +500.0% | 6,186 | +192.8% | 0.00% | – |
| Q3 2019 | $2,000 | -94.6% | 2,113 | -87.5% | 0.00% | – |
| Q2 2019 | $37,000 | -53.2% | 16,854 | +27.2% | 0.00% | – |
| Q1 2019 | $79,000 | +163.3% | 13,253 | +231.9% | 0.00% | – |
| Q4 2018 | $30,000 | +2900.0% | 3,993 | +3200.0% | 0.00% | – |
| Q3 2018 | $1,000 | 0.0% | 121 | +98.4% | 0.00% | – |
| Q2 2018 | $1,000 | -50.0% | 61 | -48.7% | 0.00% | – |
| Q1 2018 | $2,000 | -60.0% | 119 | -40.5% | 0.00% | – |
| Q4 2017 | $5,000 | +150.0% | 200 | +170.3% | 0.00% | – |
| Q3 2017 | $2,000 | -98.3% | 74 | -98.3% | 0.00% | – |
| Q2 2017 | $117,000 | +148.9% | 4,313 | +171.8% | 0.00% | – |
| Q1 2017 | $47,000 | -84.9% | 1,587 | -86.2% | 0.00% | – |
| Q4 2016 | $311,000 | +1313.6% | 11,471 | +1243.2% | 0.00% | – |
| Q3 2016 | $22,000 | +22.2% | 854 | -12.9% | 0.00% | – |
| Q2 2016 | $18,000 | -88.8% | 981 | -88.4% | 0.00% | – |
| Q1 2016 | $161,000 | +242.6% | 8,490 | +389.1% | 0.00% | – |
| Q4 2015 | $47,000 | – | 1,736 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |